A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
City of Hope Medical Center
American Regent, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Daiichi Sankyo
Massachusetts General Hospital
Icahn School of Medicine at Mount Sinai